Introducing the Galleri multi-cancer early detection test

Galleri is a blood test that can detect 50+ cancer types and can be taken annually.1,2

Request your Galleri test
Already have an account? Log in

The Galleri test is available by prescription only. The Galleri test does not detect a signal for all cancers, and false positive or false negative results can occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.

Cindy testimonial preview

Patient Story: Cindy, Cancer Signal Detected with the Galleri test

Patient Story: Cindy, Cancer Signal Detected with the Galleri test

The Galleri test is available by prescription only. The Galleri test does not detect a signal for all cancers, and false positive or false negative results can occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.

Who is eligible?

The Galleri test is available as an included benefit to employees enrolled in an Okta medical plan and covered spouses/partners that also meet the following criteria:

Employees

  • Enrolled in an Okta medical plan 
  • 50 years and older 
  • 35-49 with certain risk factors
  • 35-49 years old AND at least one of the following risk factors:
    • Cancer survivor who has completed treatment at least 3 years ago*
    • Currently smokes or quit smoking less than 10 years ago
    • Diagnosis of cirrhosis or chronic hepatitis B or C infection
    • Infection with certain strains of HPV (e.g., HPV 16 or 18)
    • Known hereditary cancer syndrome
      • Confirmation or documentation of a gene mutation associated with increased cancer risk (e.g., Li-Fraumeni syndrome, hereditary breast and ovarian cancer syndrome [BRCA1/2], Lynch syndrome, and CHEK2).
  • 35-49 years old AND at least two of the following risk factors:
    • Documented genetic predisposition (germline variant)
    • First-degree relative with cancer†
    • History of HIV infection
    • Current use of immunosuppressive therapies after solid organ transplant
    • Diabetes
    • BMI:
      • Female ≥ 30 kg/m2
      • Male ≥ 35 kg/m2

*Excludes basal or squamous cell carcinoma of the skin.

†Excludes basal or squamous cell carcinoma of the skin and/or the second cancer is not a recurrence or metastasis.

Please note that the Galleri test is not available for people who are currently pregnant or undergoing cancer treatment.

woman with brown hair wearing a tan sweater and gray pants smiling softly and sitting on a chair in her living room

Spouses/Domestic Partners

  • Enrolled in an Okta medical plan
  • 50 years and older 
  • 35-49 with certain risk factors
  • 35-49 years old AND at least one of the following risk factors:
    • Cancer survivor who has completed treatment at least 3 years ago*
    • Currently smokes or quit smoking less than 10 years ago
    • Diagnosis of cirrhosis or chronic hepatitis B or C infection
    • Infection with certain strains of HPV (e.g., HPV 16 or 18)
    • Known hereditary cancer syndrome
      • Confirmation or documentation of a gene mutation associated with increased cancer risk (e.g., Li-Fraumeni syndrome, hereditary breast and ovarian cancer syndrome [BRCA1/2], Lynch syndrome, and CHEK2).
  • 35-49 years old AND at least two of the following risk factors:
    • Documented genetic predisposition (germline variant)
    • First-degree relative with cancer†
    • History of HIV infection
    • Current use of immunosuppressive therapies after solid organ transplant
    • Diabetes
    • BMI:
      • Female ≥ 30 kg/m2
      • Male ≥ 35 kg/m2
         

*Excludes basal or squamous cell carcinoma of the skin.

†Excludes basal or squamous cell carcinoma of the skin and/or the second cancer is not a recurrence or metastasis.

Please note that the Galleri test is not available for people who are currently pregnant or undergoing cancer treatment.

Black couple sitting at their kitchen table writing on a notepad with a cup of coffee and a tablet on the table in front of them
Already have an account? Log in

Limited data exists regarding the performance of the Galleri test in individuals <50 years of age.2,3,4

Galleri for Okta

You will be asked for your Access ID to request the Galleri test. 

For Okta employees, your Access ID will be your Employee ID, which can be found in Workday. 

Spouses of Okta employees should enter their partner's Employee ID below and complete the remainder of the Galleri order with their personal information.

Galleri is available as an included benefit to employees enrolled in an Okta health plan and their covered spouse/domestic partner who are age 50+ or 35-49 with risk factors.

To create an account, use your personal email address.

Screen for more in 4 simple steps

illustrated graphic of a Black male doctor in a white lab coat reading a chart

Request the test

It will take about 10 minutes to complete an online health questionnaire about your medical history. The Galleri test, by GRAIL, is available by prescription only. By requesting the test and completing the questionnaire, you’re requesting a prescription from Recuro Health, an independent telemedicine provider.

illustrated graphic of the Galleri test box sitting on a table in front of a window

Receive a collection kit

If the Recuro Health telemedicine provider confirms your eligibility and prescribes the Galleri test, you will receive a notification via email and a collection kit in the mail. Visit Galleri.com/schedule to book your blood draw appointment at a GRAIL blood draw partner.

illustrated graphic of a white, gray haired female patient having her blood drawn

Provide your sample

Bring your test kit and Test Requisition Form (TRF) with you to the appointment. A trained technician will draw your blood sample and ship the kit to the GRAIL lab.

Illustrated graphic of a black man sitting in a blue armchair and reviewing test results on a tablet

Receive your results

Recuro Health will contact you when your result is ready — about 2-3 weeks after your blood is received at the GRAIL lab.

Already have an account? Log in

What does the Galleri test result mean?


The Galleri test detected DNA fragments associated with cancer in your blood sample. About 1 out of every 100 test has a Cancer Signal Detected result.4

This result will also include a prediction of the issue type or organ associated with the cancer signal, called a Cancer Signal Origin (CSO). This provides direction to your doctor on the cancer’s origin and can help guide the next steps for diagnosis.2,5

In a clinical study, around 6 out of 10 people with a Cancer Signal Detected result were diagnosed with cancer after diagnostic testing.6*

*Based on the first ~25,000 participants with 1 year of follow-up. 

The Galleri test does not detect a signal for all cancers, and false positive or false negative results can occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.

Cancer signal detected thumb
NEXT STEPS

A Cancer Signal Detected test result is not a cancer diagnosis and requires follow-up diagnostic testing. Such testing may include lab work or imagining ordered by your healthcare provider to confirm cancer.

The Galleri test did not detect DNA fragments associated with cancer in your blood sample. 

Nearly 99% of people who use the Galleri test will screen negative.4

This result does not completely rule out the possibility of cancer. While the Galleri test is a powerful tool, it cannot detect a signal for all cancers and not all cancers can be detected in the blood. Some cancers shed little or no DNA into the bloodstream, making them unlikely to be detected through a blood test (e.g., brain, skin, and early-stage breast and prostate cancers).7 False positive and false negative results do occur. This result does not predict whether you will develop cancer in the future. 

Cancer signal not detected thumb
NEXT STEPS

Continue with any routine cancer screenings your healthcare provider recommends. Do not ignore cancer signs or symptoms if they occur, as this could lead to delayed diagnosis.

Cancer can be unpredictable. The Galleri test can be taken as a simple blood test. Adding the Galleri test to an annual routine can improve your chance of finding cancer early.8

Cancer screening with Galleri can make a difference

Galleri looks for many deadly cancers before symptoms appear from a single blood draw and identifies a unique “fingerprint” of 50+ cancers, including many without a recommended screening available today.
  • Jackiecompressed

    Patient testimonial: Jackie

    Cancer Signal Detected
    Read Jackie's full story

  • Cindy testimonial preview

    Patient testimonial: Cindy

    Cancer Signal Detected

  • Jonathan Testimonial Lyphoma

    Patient testimonial: Jonathan

    Cancer Signal Detected

  • Rich testimonials

    Patient testimonial: Rich

    Cancer Signal Detected

  • Mary patient vid

    Patient testimonial: Mary

    Cancer Signal Detected

  • Roger testimonial

    Patient testimonial: Roger

    Cancer Signal Detected

  • Valerie

    Patient testimonial: Valerie

    Cancer Signal Detected

  • Patient story video still closeup of Tami

    Patient testimonial: Tami

    No Cancer Signal Detected

  • patient story video still of Keith and his wife on a walk

    Patient testimonial: Keith

    No Cancer Signal Detected

  • Jennifer Testimonial poster

    Patient testimonial: Jennifer

    No Cancer Signal Detected
    Read Jennifer's full story

  • Rich S Taci

    Patient testimonial: Rich & Staci

    Cancer Signal Detected
    Read Rich & Staci's full story

  • Oncologist perspective

    Oncologist Perspectives

1 / 12

Frequently Asked Questions for Okta

Additional Frequently Asked Questions about the Galleri test

The Galleri test is available as an included benefit to employees enrolled in an Okta medical plan and covered spouses/partners that are 50+ or 35-49 with elevated risk factors.

The test is covered by Okta with no out of pocket expense for the employee. Any additional testing would be subject to regular medical plan processing and cost structure.

At least one of the following:

  • Cancer survivor who has completed treatment within the last three years*
  • Currently smokes or quit smoking within the last 10 years
  • Diagnosis of cirrhosis or chronic Hepatitis B or C infection
  • Infection with certain strains of HPV (e.g. HPV 16 or 18)
  • Known hereditary cancer syndrome
    • Confirmation or documentation of a gene mutation associated with increased cancer risk (e.g., Li-Fraumeni syndrome, Hereditary Breast and Ovarian Cancer syndrome [BRCA1/2], Lynch syndrome, CHEK2).

-OR-

At least two of the following:

  • Documented genetic predisposition (germline variant)
  • First degree relative with cancer**
  • History of HIV infection
  • Current use of immunosuppressive therapies after organ transplantation
  • Diabetes
  • BMI:
    • Female ≥ 30
    • Male ≥ 35

*excludes basal or squamous cell carcinoma of the skin

**excludes basal or squamous cell carcinoma of the skin and/or the second cancer is not a recurrence or metastasis

Your Access ID is your Employee ID, which can be found in Workday.

To access the Galleri test as a covered benefit, you must request the test through this webpage.

When requesting through this website, an independent healthcare provider from Recuro Health will review your request and order the test if appropriate. The test is prescription only.

To access the Galleri test as a covered benefit, you must request the test through this web page. An independent physician from Recuro Health will review your request and order the test, if appropriate.

Under the Okta benefit program, eligible employees and spouses/domestic partners will be able to complete the Galleri test every year.

Get support

For questions about the Galleri test, please contact GRAIL Customer Service:

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. The test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. The Galleri test is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed — and its performance characteristics were determined — by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes

  1. US Preventive Services Task Force. A,B,C grade recommendations, cancer, screening [cited 2025 Mar 18]. https://www.uspreventiveservicestaskforce.org/uspstf/topic_search_results
  2. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-77. doi: 10.1016/j.annonc.2021.05.806
  3. Matrana M, Shukla V, Kingsbury D, et al. Real‑world data and clinical experience from over 100,000 multi‑cancer early detection tests [poster]. American Association for Cancer Research (AACR) Annual Meeting; 2025 Apr 25-30; Chicago. https://assets.grail.com/wp-content/uploads/2025/04/7202.Matrana.AACR-2025-RWE-100K_Poster_Final.pdf
  4. Schrag D, Beer TM, McDonnell CH, et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402(10409):1251-60. doi: 10.1016/S0140-6736(23)01700-2
  5. GRAIL, Inc. Enhanced Cancer Signal Origin prediction. [Data on file: VV-TMF-59592]
  6. Nabavizadeh N, et al. Safety and performance of a multi-cancer early detection (MCED) test in an intended-use population: initial results from the registrational PATHFINDER2 study [proffered presentation]. European Society for Medical Oncology (ESMO) Annual meeting: 2025 Oct 17-21; Berlin.
  7. Bredno J, Venn O, Chen X, et al. Circulating tumor DNA allele fraction: a candidate biological signal for multi-cancer early detection tests to assess the clinical significance of cancers. Am J Pathol. 2022; 192(10):1368-78. doi:10.1016/j.ajpath.2022.07.007
  8. Sasieni P, Clarke CA, Hubbell E. Impact of MCED screening interval on reduction in late-stage cancer diagnosis and mortality. European Society for Medical Oncology (ESMO) Virtual Congress [poster]; 2021 Sep 16-21.